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HX4Background and purpose: [18F]HX4 is a promising hypoxia PET-tracer. Uptake, spatio-temporal stability
and optimal acquisition parameters for [18F]HX4 PET imaging were evaluated in non-small cell lung can-
cer (NSCLC) patients.
Materials and methods: [18F]HX4 PET/CT images of 15 NSCLC patients were acquired 2 h and 4 h after
injection (p.i.). Maximum standardized-uptake-value (SUVmax), tumor-to-blood-ratio (TBRmax), hypoxic
fraction (HF) and contrast-to-noise-ratio (CNR) were determined for all lesions. To evaluate spatio-tem-
poral stability, DICE-similarity and Pearson correlation coefﬁcients were calculated. Optimal acquisition-
duration was assessed by comparing 30, 20, 10 and 5 min acquisitions.
Results: Considerable uptake (TBR >1.4) was observed in 18/25 target lesions. TBRmax increased signiﬁ-
cantly from 2 h (1.6 ± 0.3) to 4 h p.i. (2.0 ± 0.6). Uptake patterns at 2 h and 4 h p.i. showed a strong cor-
relation (R = 0.77 ± 0.10) with a DICE similarity coefﬁcient of 0.69 ± 0.08 for the 30% highest uptake
volume. Reducing acquisition-time resulted in signiﬁcant changes in SUVmax and CNR. TBRmax and HF
were only affected for scan-times of 5 min.
Conclusions: The majority of NSCLC lesions showed considerable [18F]HX4 uptake. The heterogeneous
uptake pattern was stable between 2 h and 4 h p.i. [18F]HX4 PET imaging at 4 h p.i. is superior to 2 h
p.i. to reach highest contrast. Acquisition time may be reduced to 10 min without signiﬁcant effects on
TBRmax and HF.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 109 (2013) 58–64
Open access under CC BY-NC-ND license.Radiotherapy combined with chemotherapy is the standard
treatment modality for patients with locally advanced non-small
cell lung cancer (NSCLC). Unfortunately, after treatment, progres-
sion free survival is shortwith amedianof 14 months [1]. Tumor cell
hypoxia is known to be a major factor that negatively inﬂuences
treatment effectiveness, it promotes resistance to radiotherapy
and chemotherapy and increases tumor aggressiveness, angiogene-
sis, and metastatic potential, resulting in a poor prognosis. [2,3].
Detection and quantiﬁcation of tumor cell hypoxia using non-
invasive positron emission tomography (PET) could help selectingpatients who may beneﬁt from treatment adaptation counteract-
ing hypoxia [4,5]. The selective binding and retention of 2-nitroim-
idazoles allows detection and quantiﬁcation of tumor hypoxia with
PET imaging prior to and during treatment [6–11]. In addition, it
provides the opportunity to display the spatial distribution of hy-
poxia, which is essential for its integration in radiation dose distri-
bution [12]. An increased radiation dose to the radio-resistant/
hypoxic areas may result in an increased local control [13–15].
Therefore accurate identiﬁcation and stable detection of the in-
tra-tumor hypoxic sub-volumes is of importance [16].
Several 2-nitroimidazoles, labeled with ﬂuor-18 [18F], have al-
ready been applied in patients to identify hypoxia [17]. The 2-
nitroimidazole nucleoside analog: 3-[18F]ﬂuoro-2-(4-((2-nitro-
1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol[18F]
HX4, was developed as a potential marker to visualize hypoxic tu-
mor cells [18]. It has a high water solubility and fast clearance from
non-hypoxic tissue, therefore generating a tracer with preferred
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ical studies have shown that [18F]HX4 is a promising and non-toxic
tracer to visualize tumor hypoxia [18–21]. Imaging data is avail-
able at www.cancerdata.org/?q=10.1073/pnas.1102526108 and
www.cancerdata.org/?q=10.1007/s00259-010-1437-x. In a rat
rhabdomyosarcoma model the [18F]HX4 PET contrast (tumor-to-
blood ratio; TBR) increased signiﬁcantly over time, reaching a pla-
teau and optimal imaging at 4 h after injection [18]. In an inter-pa-
tient comparison [18F]HX4 yielded a similar tumor-to-muscle ratio
at 1.5 h post-injection (p.i.) than [18F]MISO at 2 h p.i., suggesting
that [18F]HX4 may be used with a shorter injection-acquisition
time than [18F]MISO [21].
The aims of this study were to evaluate the [18F]HX4 uptake in
NSCLC patients, to report spatio-temporal stability, compare imag-
ing at different time-points and evaluate the possibility to reduce
acquisition time.
Materials and methods
Patients
Fifteen NSCLC patients analyzed in this study were included in
the PET-Boost [15] (NCT01024829) or Nitroglycerin trial
(NCT01210378), approved by the appropriate Medical Ethics Re-
view Committee. Written informed consent was obtained from
all patients before study entry.
[18F]HX4 PET/CT imaging was acquired at baseline, i.e. before
the start of external beam radiotherapy. However, patients were
treated with concurrent or sequential chemoradiation and received
at least one course of chemotherapy before the start of radiother-
apy and [18F]HX4 PET/CT imaging.
PET/CT imaging
Images were acquired on a Philips Gemini TF 64 PET/CT scanner
(Philips Healthcare, Best, The Netherlands) with an axial ﬁeld of
view of 18 cm, slice thickness of 4 mm, in plane pixel spacing of
4 mm and a spatial resolution of approximately 5 mm FWHM. CT
based attenuation correction and scatter correction (SS-SIMUL)
were performed. The PET images were reconstructed using 3D or-
dered-subset iterative time-of-ﬂight reconstruction technique
(BLOB-OS-TF) using 3 iterations and 33 subsets. The patient was
scanned in radiotherapy position, positioned on a ﬂat tabletop
using a movable laser alignment system with the arms in an
arm-support positioned above the head. The ﬁeld of view for CT
and PET imaging was positioned on the primary tumor. [18F]HX4
was produced as described in previous publications [18–21]. The
injected activity of [18F]HX4 was 423 ± 72 MBq based on a previous
phase I trial [19]. After intravenous administration of [18F]HX4,
PET/CT imaging was performed at 2 h and 4 h p.i. A single bed-po-
sition PET was acquired with a total acquisition time of 30 min.
Analysis
Gross tumor volumes of the primary tumor (GTVprim) and in-
volved lymph nodes (GTVln) were deﬁned by an experienced radi-
ation oncologist and evaluated by a second radiation oncologist, on
the [18F]ﬂuorodeoxyglucose (FDG) PET/CT scan used for radiother-
apy planning purposes, acquired in the same week as the [18F]HX4
PET/CT. [18F]FDG-based GTVs were copied to the [18F]HX4 PET/CT
images by rigid registration and a visual check was performed.
No matching problems occurred. In addition a volume of interest
(VOI) in the aorta was deﬁned as background region.
Scan time point
The optimal imaging time point was evaluated by determining
image parameters in the 2 h and 4 h p.i. [18F]HX4 PET scans. Themean and maximum standardized uptake values (SUVmean and
SUVmax, respectively) in the GTVs and aorta were extracted (PMOD
v3.0, Zurich, Switzerland). The tumor-to-background ratio (TBRmax)
was deﬁned as the ratio of GTV SUVmax and aorta SUVmean. The tu-
mor hypoxic fraction (HF) was calculated based on the [18F]HX4
uptake. A threshold for the deﬁnition of hypoxia has not been for-
mally established, based on previous publications, a TBR larger
than 1.4 was used as the standard threshold to deﬁne tumor hy-
poxia [18,22–24]. In addition, the HF was calculated based on a
threshold ranging from TBR >1.1 to TBR >1.6.Spatio-temporal stability
The spatio-temporal stability was evaluated using two meth-
ods, ﬁrst by calculating the DICE similarity coefﬁcient of the hyp-
oxic volumes and second with a voxel-wise comparison of the
[18F]HX4 uptake at 2 h and 4 h p.i. For both methods the CT ac-
quired at 2 h p.i. (CT2h) was rigidly registered to the CT at 4 h p.i.
(CT4h). The resulting deformation ﬁeld was applied to co-register
the PET at 2 h p.i. (PET2h) to the PET at 4 h p.i. (PET4h).
To calculate the DICE similarity coefﬁcient; First the percentile
of the GTV with the highest uptake on PET2h and PET4h was de-
ﬁned, by using percentiles ranging from 50% to 90%. Second, only
for lesions with a HF >5%, the hypoxic volume on the PET4h and
its corresponding high uptake volume on the PET2h were deﬁned.
The resulting high uptake volumes (UV) are represented by UV2h
and UV4h. DICE was calculated using:
DICE ¼ 2 UV2h \ UV4h
UV2h þ UV4h
Furthermore, a voxel-wise comparison of the [18F]HX4 PET up-
take in the GTV in PET2h and PET4h was performed.Reduced acquisition time
Because hypoxia PET tracers generally have a low uptake in tu-
mors, prolonged PET acquisition timesmay be preferred. Additional
reconstructions were made with reduced acquisition duration. The
full acquisition time of 30 min was compared to the ﬁrst 20, 10 and
5 min acquisitions by evaluating changes in SUVmax, TBRmax, HF and
the contrast-to-noise ratio (CNR) deﬁned as:
CNR ¼ SUVmax tumor SUVmean aorta
SUVSD aortaStatistics
For all parameters mean ± 1 standard deviation (SD) are re-
ported. A Wilcoxon signed rank test was used to determine signif-
icant differences in uptake (SUVmax, TBRmax) between 2 h and 4 h
p.i. and to evaluate the effect on image parameters (SUVmax,
TBRmax, HF, CNR) when limiting the acquisition time. Linear regres-
sion was performed to correlate SUVmax and TBRmax from 2 h to 4 h
p.i. and to quantify the voxel-wise comparison of the [18F]HX4 up-
take within the GTV. Slope and Pearson correlation coefﬁcients
were calculated. A p-value smaller than 0.05 was assumed to be
statistically signiﬁcant.
Results
[18F]HX4 PET/CT imaging of 15 NSCLC patients (11 male, 4 fe-
male) was included in the analysis. The mean age of the patients
was 62 ± 10 years (range 40–82years). Tumor stage ranged from
IIB to IV; pathology being adenocarcinoma (n = 8), squamous cell
carcinoma (n = 3), large cell carcinoma (n = 3) or not speciﬁed
(n = 1). All patients were treated with curative intent and had
Table 1
Patient characteristics.
Patient Age Gender TNM Stage Pathology GTV Size GTV [cm3] Prior treatment
[no. chemotherapy cycles]
1 55 M T2aN3M0 IIIB Large cell carcinoma prim 48 1
ln 190
2 59 F T4N1M0 IIIB Adenocarcinoma prim 328 3
ln 25
3 72 M T2N3M0 IIIB Adenocarcinoma prim 42 1
ln 51
4 60 M T4N1M0 IIIB Adenocarcinoma prim 859 1
ln⁄ 8
5 65 M T3N2M0 IIIA Squamous cell carcinoma prim 148 1
ln 39
6 66 M T2N3M0 IIIB Unknown prim 78 1
ln 13
7 51 F T3N2M0 IIIA Large cell carcinoma prim 150 2
ln 11
8 82 M T3N0M0 IIB Adenocarcinoma prim 63 3
9 66 M T4N3M0 IIIB Adenocarcinoma prim 65 2
lna 3
10 62 F T4N2M0 IIIB Squamous cell carcinoma prim 150 1
lna 5
11 77 M T3N2M0 IIIA Large cell carcinoma prim 299 1
ln⁄ 7
12 64 M T4N2M0 IIIB Squamous cell carcinoma prim 212 1
ln 13
13 60 M T4N2M0 IIIB Adenocarcinoma prim 53 2
ln 17
14 47 F T4N3M0 IIIB Adenocarcinoma prim 125 1
ln 204
15 40 M T4N2M1 IV Adenocarcinoma prim 78 3
ln 35
prim = primary lesion, ln = involved lymph nodes.
a Lesions with a volume <10 cm3.
Fig. 1. Example of two transversal slices of the [18F]HX4 CT/PET image of patient 14 at 2 h and 4 h p.i. showing the primary tumor (GTVprim) and involved lymph nodes
(GTVln).
60 Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Deﬁning optimal imaging parametersone to three cycles of chemotherapy before hypoxia PET imaging
and the start of radiotherapy. Patient characteristics are visualized
in Table 1. All but one patient had involvement of the lymph nodes(GTVln) which were separately analyzed from the primary tumor
(GTVprim). Four involved lymph nodes with a volume <10 cm3 were
excluded, due to potential partial volume effects. As a result 25
Table 2
Target lesion characteristics at 2 h and 4 h p.i.
Patient Lesion GTV [cm3] Tumor SUVmax Aorta SUVmean TBR
2 h p.i. 4 h p.i. 2 h p.i. 4 h p.i. 2 h p.i. 4 h p.i.
1 prim 48 0.93 0.64 0.88 0.58 1.06 1.10
lnc 190 1.63 1.65 1.87 2.84
2 primc 328 2.19 1.84 0.91 0.53 2.40 3.47
lnc 25 1.63 1.36 1.79 2.56
3 primc 42 0.73b 0.65b 0.48b 0.36b 1.51 1.78
Ln 51 0.63b 0.48b 1.30 1.33
4 primc 859 0.87b 0.85b 0.51b 0.34b 1.71 2.52
lna 8 0.55b 0.44b 1.08 1.32
5 primc 148 1.47 1.30 0.98 0.71 1.50 1.83
lnc 39 1.23 1.03 1.26 1.45
6 primc 78 1.49 1.44 0.79 0.62 1.90 2.33
Ln 13 1.14 0.98 1.45 1.58
7 primc 150 0.91 0.66 0.67 0.44 1.36 1.49
ln 11 0.73 0.51 1.08 1.15
8 primc 63 1.45 1.63 1.02 0.85 1.43 1.92
–
9 prim 65 1.01 0.76 0.85 0.60 1.19 1.26
lna 3 0.81 0.59 0.95 0.99
10 primc 150 1.28 1.09 0.96 0.62 1.34 1.75
lna,c 5 1.29 1.24 1.35 2.00
11 primc 299 1.98 1.87 1.18 1.02 1.69 1.83
lna 7 1.33 1.28 1.13 1.25
12 primc 212 2.03 1.97 1.33 1.06 1.53 1.85
Ln 13 1.39 1.14 1.04 1.07
13 prim 53 1.00 0.76 0.86 0.56 1.17 1.34
Ln 17 0.89 0.70 1.04 1.24
14 primc 125 1.12 1.02 0.81 0.54 1.37 1.90
lnc 204 1.19 1.28 1.46 2.37
15 primc 78 1.40 1.13 1.10 0.78 1.27 1.45
lnc 35 1.32 1.19 1.20 1.52
Average [>10 cm2] 132 ± 175 1.34 ± 0.39 1.18 ± 0.43 0.95 ± 0.18 0.69 ± 0.19 1.44 ± 0.32 1.80 ± 0.60
Average [hypoxic >10 cm2] 169 ± 195 1.47 ± 0.36 1.34 ± 0.37 1.56 ± 0.30 2.03 ± 0.55
a Lesions <10 cm2.
b No absolute SUV.
c Hypoxic lesions.
Fig. 2. TBRmax of the primary tumor (GTVprim) and involved lymph nodes (GTVln) of
all patients.
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ysis, with an average lesion size of 180 ± 208 cm3 (range 42–
859 cm3) for primary tumor and 60 ± 74 cm3 (range 11–204 cm3)
for the sum of the pathological lymph nodes.
For two patients (P3 and P4) the SUV values could not be deter-
mined due to an undeﬁned amount of residual activity in the
administration system. For these patients, absolute SUV was calcu-
lated based on the estimated activity in the syringe before injec-
tion, but excluded from statistical analysis. TBRmax, HF and CNR
calculations were not affected by this spill and therefore included
in the analysis.
Tumor hypoxia, deﬁned as TBRmax >1.4 on the 4 h p.i. acquisi-
tion, was observed in 80% (12/15) of the primary tumors and 60%
(6/10) of lymph node regions. An example of a 2 h and 4 h p.i.
PET/CT image is shown in Fig. 1. Comparing 2 h with 4 h p.i., there
was a high correlation for both SUVmax (R = 0.96) and TBRmax
(R = 0.94).
Within the hypoxic lesions, the tumor SUVmax decreased be-
tween 2 h p.i. and 4 h p.i. for both GTVprim (1.5 ± 0.4 to 1.4 ± 0.4;
P < 0.001) and GTVln (1.4 ± 0.2 to 1.2 ± 0.2; P = 0.16). However,
due to clearance of [18F]HX4 in the blood, the TBRmax increased sig-
niﬁcantly from 2 h to 4 h p.i. (GTVprim: 1.6 ± 0.3 to 2.0 ± 0.6;
P < 0.001 and GTVln: 1.5 ± 0.3 to 2.1 ± 0.6; P = 0.03) as shown in Ta-
ble 2 and Fig. 2. The SUVmean measured within the aorta VOI was
1.0 ± 0.2 and 0.7 ± 0.2 at 2 h p.i. and 4 h p.i., respectively. Assuming
an exponential clearance of HX4 in the blood, this resulted in an
estimated biological half life of 4.3 h.
The average HF (TBR >1.4), based on the 4 h p.i. image, was
15 ± 19% (GTVprim, range 0.1–66%) and 12 ± 13% (GTVln, range
Fig. 3. Example of patient 8. Left ﬁgure shows the 2 h p.i. [18F]HX4 PET/CT that is rigidly registered to the 4 h p.i. scan (middle). Visualized are the gross tumor volume (blue)
and the hypoxic volume in the 4 h p.i. scan and its corresponding high uptake volume in the 2 h p.i. scan (red). The right ﬁgure shows the voxel-wise comparison between 2 h
and 4 h p.i. within the gross tumor volume.
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and HF was observed (R = 0.12, P = 0.57). When applying the same
threshold (TBR >1.4) in the 2 h p.i. images, a lower amount of hyp-
oxic lesions were detected (8/15 GTVprim and 4/10 GTVln) and the
average HF was reduced to 5 ± 10% (GTVprim) and 3 ± 6% (GTVln).
Using a threshold of TBR >1.2 resulted in a similar hypoxic lesion
detection rate (12/15 and 7/10, respectively) and HF (GTVprim
17 ± 17% and GTVln 10 ± 10%) compared to 4 h p.i., however the
use of this lower threshold resulted in one false positive case.
The hypoxic fractions based on thresholds ranging from TBR >1.1
to TBR >1.6 on both 2 h and 4 h p.i. acquisitions are summarized
in Table S1.
Although the hypoxic lesions showed a heterogeneous [18F]HX4
uptake pattern, the voxel-wise comparison of the PET2h and PET4h
showed a strong correlation (R = 0.77 ± 0.10, range: 0.58–0.94,
slope: 0.72 ± 0.15), see Fig. 3 and Table S2. Comparing high uptake
percentiles resulted in an average DICE similarity coefﬁcient of
0.79 ± 0.06, 0.75 ± 0.06, 0.70 ± 0.08, 0.61 ± 0.10 and 0.48 ± 0.10 for
the highest volume percentiles 50%, 60%, 70%, 80% and 90%, respec-
tively. Comparing the hypoxic volumes deﬁned on the PET4h with
the corresponding high uptake volume on the PET2h provides a
DICE similarity coefﬁcient of 0.61 ± 0.19 (Table S2).
One patient was excluded from this analysis due to an incom-
plete 30 min acquisition, resulting in 16 evaluable hypoxic lesions
(>10 cm3). Reducing acquisition time from 30 min to the ﬁrst 20,
10 and 5 min of the acquisition resulted in an average increase in
SUVmax of 4 ± 6% (P = 0.014), 12 ± 15% (P < 0.001) and 18 ± 16%
(P = 0.025). TBRmax increased with 2 ± 5% (P = 0.171), 7 ± 12%
(P = 0.074) and 16 ± 13% (P < 0.001) for, respectively, the 20, 10
and 5 min acquisition, hence only a signiﬁcant difference was
reached for the 5 min acquisition. The average HF was not
signiﬁcantly different for the 30 min (11 ± 16%), 20 min
(11 ± 16%) and 10 min (11 ± 15%) acquisition, again for the 5 min
acquisition (average HF: 13 ± 15%) the change in HF was signiﬁcant
(P = 0.02). The CNR decreased from 9.5 ± 4.1 (30 min) to 8.7 ± 4.2
(20 min; P = 0.02), 7.8 ± 4.7 (10 min; P < 0.01) and 6.6 ± 3.2Fig. 4. Transversal [18F]HX4 PET slice of patient 4 at 4 h p.i., reconstructe(5 min; P < 0.001). Images of an example patient are visualized in
Fig. 4.
Discussion
The aims of this study were to evaluate [18F]HX4 uptake in
NSCLC, report spatio-temporal stability, compare imaging at differ-
ent time-points and evaluate the possibility to reduce acquisition
time. Based on this, we want to generate recommendations for fu-
ture PET imaging with [18F]HX4. [18F]HX4 was developed to pro-
vide a hypoxia PET tracer with preferred pharmacokinetic and
clearance properties compared to other available nitroimidazoles.
Based on the current population the biological half-life of HX4 in
the blood is approximately 4.3 h. Which is a 3-fold faster clearance
in comparison to [18F]MISO, reported to have a biological half life
of 12–13 h [25,26]. In a clinical trial, it was shown that [18F]HX4
provides the same image contrast as [18F]MISO at an earlier
time-point after injection [21], a characteristic beneﬁcial for prac-
tical reasons. However, previous preclinical and clinical studies
have also shown that for both FMISO [6,27] and HX4 [18,19] the la-
ter scan time-points are optimal in order to reach a higher image
contrast. In the current study the image contrast (TBRmax) in-
creased from 2 h to 4 h p.i. conﬁrming the pre-clinical results, i.e.
[18F]HX4 scanning at 4 h p.i. provides a better opportunity to iden-
tify hypoxic areas. In preclinical setting a TBR plateau was reached
at 4 h p.i., however it is still unknown if in the clinical situation, hy-
poxia imaging at a timepoint later than 4 h p.i. could provide an en-
hanced image contrast [18].
In literature no evaluation has been performed comparing all
hypoxia PET tracers in the same tumor model or patient population
[17]. Hence, it is difﬁcult to compare the current results to clinical
trials with other hypoxia tracers used in NSCLC imaging. Other
studies allowed different treatment modalities before imaging,
with differences in scan time p.i. or deﬁnition of background tissue
(muscle [7], mediastinum [6,28], venous blood sampling [22,29],
lung [30], heart [31], not speciﬁed [32]). Nevertheless it seems thatd with the total acquisition of 30 min or the ﬁrst 20, 10 and 5 min.
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compared to other trials with [18F]FMISO [6–8,30], FAZA [32] or
FETNIM [29].
The deﬁnition of the hypoxic volume in the literature is diverse
and based on different tracers. For [18F]FMISO imaging, a compar-
ison with immunohistochemistry [24], normal tissue differences
[22] and in vivo bio-distribution data [23] a threshold of TBR
>1.4 can be supported. For [18F]HX4 imaging a good correlation
with immunohistochemistry was observed when HX4 positive
voxels (TBR >1.4) were compared to pimonidazole staining [18],
however the optimal TBR in a clinical setting is still under investi-
gation. Using the TBR >1.4 threshold a signiﬁcant amount of tumor
hypoxia was observed in 80% of the primary tumors and 60% of the
involved lymph nodes. Note that although the lesion size of GTVln
was in general smaller than GTVprim, still no relationship was found
between GTV and HF. An average HF of 14 ± 17% was observed,
which is lower in comparison to a previous study of Rasey et al.
[22] where a median HF of 58% was reported. The discrepancy
might be explained due to the fact that all patients in the current
study had at least one cycle of chemotherapy before [18F]HX4
PET scans, which may reduce tumor hypoxia [9,33], resulting in a
lower SUVmax, TBR and HF. Note that, this is a situation frequently
occurring in clinical practice. However, the hypoxic status of the le-
sion was assessed before the start of radiotherapy, which is of ut-
most importance in dose redistribution strategies.
The TBR threshold of 1.4 should not be interpreted as a rigid va-
lue to determine tumor hypoxia. Due to tracer kinetics, the thresh-
old should be optimized based on scan time post-injection. An
alternative threshold of TBR >1.2, also used in several trials
[31,34,35], provides in the current study a similar amount of de-
tected lesions at 2 h p.i. in comparison to 4 h p.i. using a TBR
>1.4, however the risk of misclassifying lesions increases. This
might also explain the difference between the studies of Nehmeh
et al. [34] and Okamoto et al. [36] using [18F]MISO PET imaging
in head and neck cancer patients. Nehmeh et al. used a threshold
of TBR >1.2 and observed that the measured fractional hypoxic vol-
umes were variable over time. Whereas Okamoto et al. using a
threshold of TBR >1.4 found a high reproducibility of tumor hypox-
ia. In the ideal situation, clinical PET imaging should be correlated
with tumor pathological specimens [37], to evaluate the threshold
to deﬁne tumor hypoxia.
For future dose re-distribution studies it is of importance to
gain insight into the spatio-temporal stability of the PET tracer. A
rigid registration was performed to compare the [18F]HX4 PET
images at 2 h and 4 h p.i. Small errors in the registration can
strongly affect the observed correlations negatively [38]. In the
current study PET scans were acquired in treatment position
reducing the possibility for registration errors. Patients were
free-breathing during PET-acquisitions, which might cause a blur-
ring of the PET signal. However, this will not affect the registration,
since breathing motion is the same for both acquisitions. By using a
careful scan procedure and image registration a good spatio-tem-
poral stability was found.
Limiting the acquisition time is beneﬁcial for practical reasons,
to reduce patient movement and to increase patient comfort. As
expected, image noise increases when reducing the acquisition
time. This results in a signiﬁcant change in CNR and SUVmax for
all reduced acquisition times. However TBRmax and HF are only sig-
niﬁcantly inﬂuenced when acquisition time is reduced to 5 min.
This is in agreement with the results previously showed by Boell-
aard et al. [39], that SUVmax is more sensitive to image noise than
SUV ratios like TBR. For this reason SUVmax is not the best param-
eter to evaluate the uptake of hypoxia makers. A trade-off has to be
made between image noise and practical issues, nonetheless, the
acquisition-time for [18F]HX4 PET imaging at 4 h p.i. should be at
least 10 min, with the current administered activity and a modernTime-of-Flight PET/CT scanner. This provides the opportunity to
acquire more bed positions, capturing the entire thorax in a
30 min time frame. Another option is to reduce the amount of
injected activity, which will have a similar effect on image noise
as a reduction of acquisition time.
In conclusion, signiﬁcant hypoxia was observed in 72% of the
NSCLC target lesions (80% of primary tumors and 60% of the in-
volved lymph nodes). The heterogeneous [18F]HX4 uptake pattern
was stable between 2 h and 4 h p.i., however the TBRmax increased
over time, suggesting that imaging at 4 h p.i. is better to reach the
highest contrast in [18F]HX4 PET images. [18F]HX4 PET acquisition
time can be reduced to 10 min without signiﬁcant effects on
TBRmax and HF.
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